NEW YORK, May 30, 2017 /PRNewswire/ --
This morning, Stock-Callers.com takes a closer look at Valeant Pharmaceuticals
Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock rose 0.31%, finishing last Friday's trading session at $12.83. A total volume of 8.88 million shares was traded. The Company's shares have surged 36.78% in the last month. The stock is trading above its 50-day moving average by 18.49%. Additionally, shares of Valeant Pharma, which operates as a pharmaceutical and medical device company worldwide, have a Relative Strength Index (RSI) of 57.83.
On May 22nd, 2017, Valeant Pharmaceuticals International's wholly owned subsidiary, Bausch + Lomb, announced the launch of renu® Advanced Formula multi-purpose solution for soft and silicone hydrogel contact lenses. This unique formula combines three disinfectants and two moisture agents to provide excellent lens cleaning and disinfection, in addition to all-day comfort. Your complete research report on VRX can be retrieved for free at: http://stock-callers.com/registration/?symbol=VRX
Shares in New York headquartered Delcath Systems Inc. ended at $0.02, up 2.49% from the last trading session. The stock recorded a trading volume of 48.38 million shares, which was above its three months average volume of 15.28 million shares. The Company's shares are trading 60.62% below their 50-day moving average. Moreover, shares of Delcath Systems, which focuses on the treatment of primary and metastatic liver cancers, have an RSI of 22.65.
On May 09th, 2017, Delcath Systems announced financial results for the three months ended March 31st, 2017. Revenue for the quarter was $0.74 million; selling, general and administrative expenses were approximately $2.4 million; R&D expenses were $2.3 million; total operating expenses were $4.7 million; and net loss was $11.3 million. The Company also had cash and cash equivalents of $6.4 million as of March 31st, 2017. A free report on DCTH is just a click away at: http://stock-callers.com/registration/?symbol=DCTH
On Friday, shares in Dublin, Ireland headquartered Alkermes PLC recorded a trading volume of 571,086 shares. The stock declined 0.41%, closing the day at $57.70. The Company's shares have gained 2.49% in the last one month, 4.15% over the previous three months, and 3.81% on an YTD basis. The stock is trading 6.69% above its 200-day moving average. Additionally, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide, have an RSI of 46.95. Sign up for your complimentary research report on ALKS at: http://stock-callers.com/registration/?symbol=ALKS
At the close of trading on Friday, shares in San Diego, California headquartered Adamis Pharmaceuticals Corp. recorded a trading volume of 413,665 shares. The stock finished the session 2.63% lower at $3.70. The Company's shares have gained 12.12% in the previous three months and 17.46% since the start of this year. The stock is trading above its 200-day moving average by 10.83%. Furthermore, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 43.52. Register for free on Stock-Callers.com and download the latest research report on ADMP at: http://stock-callers.com/registration/?symbol=ADMP
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All